Abstract
Late right heart failure (RHF) is increasingly recognized in patients with long-term left ventricular assist device (LVAD) support and is associated with decreased survival and increased incidence of adverse events such as gastrointestinal bleeding and stroke. Progression of right ventricular (RV) dysfunction to clinical syndrome of late RHF in patients supported with LVAD is dependent on the severity of pre-existing RV dysfunction, persistent or worsening left- or right-sided valvular heart disease, pulmonary hypertension, inadequate or excessive left ventricular unloading, and/or progression of the underlying cardiac disease. RHF likely represents a continuum of risk with early presentation and progression to late RHF. However, de novo RHF develops in a subset of patients leading to increased diuretic requirement, arrhythmias, renal and hepatic dysfunction, and heart failure hospitalizations. The distinction between isolated late RHF and RHF due to left-sided contributions is lacking in registry studies and should be the focus of future registry data collection. Potential management strategies include optimization of RV preload and afterload, neurohormonal blockade, LVAD speed optimization, and treatment of concomitant valvular disease. In this review, the authors discuss definition, pathophysiology, prevention, and management of late RHF.
| Original language | English |
|---|---|
| Pages (from-to) | 865-878 |
| Number of pages | 14 |
| Journal | JACC: Heart Failure |
| Volume | 11 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2023 |
Bibliographical note
Publisher Copyright:© 2023 American College of Cardiology Foundation
FUNDING SUPPORT AND AUTHOR DISCLOSURES
Dr Tedford has consulting relationships with Medtronic, Abbott, Aria
CV Inc, Alleviant, Acceleron, Cytokinetics, Itamar, Edwards Lifesciences, Eidos Therapeutics, Lexicon Pharmaceuticals, Gradient, and United Therapeutics; is on a steering committee for Acceleron/Merck
and Abbott; is on a research advisory board for Abiomed; and performs hemodynamic core lab work for Merck. Dr Wieselthaler is a
consultant for Medtronic. Dr Rame is a consultant for Actelion Pharmaceuticals and Abbott; was a steering committee member for the
SOPRANO study; and was a coinvestigator for the RESTAGE trial. Dr
Caliskan is a scientific advisory board member for FineHeart. All other
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.